BIIB News 297.98 04/21/2014 20:01:21 Biogen Idec Inc (BIIB)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 297.98 $BIIB

What to Watch for in Biotech Earnings This Week
George Budwell, The Motley Fool - Motley Fool - 2 hrs 31 mins ago
Biotech stocks started the year off on a tear but have moved lower lately in dramatic fashion. For instance, the iShares Nasdaq Biotech Index is now down over 2% for the year, after gaining double digits at one point in early February. Pundits and...

Will Amgen (AMGN) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 41 mins ago
Amgen has an Earnings ESP of 0.00% with a Zacks Rank #1 (Strong Buy).

Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 2.56% Rise
Comtex SmarTrend(R) - Mon Apr 21, 4:12PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $290.20 to a high of $298.57. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $296.00 on volume of 981,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 2.56% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 21, 4:11PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $290.20 to a high of $298.57. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $296.00 on volume of 981,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Will Gilead (GILD) Beat Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 9:50AM CDT
Gilead is set to report first quarter 2014 results on Apr 22 after the market closes

Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII
Marketwire - Mon Apr 21, 7:02AM CDT
Amunix Operating Inc. announced today that Biogen Idec (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties. Under the terms of the option agreement, Amunix will receive an upfront $1 million payment and will also be eligible to receive up to $38 million in clinical and commercial milestone payments. In addition, royalties will be paid on commercial sales by Biogen Idec for Factor VIII products incorporating Amunix proprietary XTEN technology.

Meet the Company That's Changing the Multiple Sclerosis Treatment Landscape
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 19, 1:05PM CDT
Here at The Motley Fool we spend a lot of time dissecting companies at the leading edge of the largest investment opportunities. Being a specialist in the Health Care sector, that means I devote a lot of my research to drugs aimed at treating some of...

This Medical Marijuana Stock Is Not What You Think
Brian Orelli, The Motley Fool - Motley Fool - Sat Apr 19, 12:30PM CDT
Despite its research into marijuana, GW Pharmaceuticals isn't going to run into legal troubles. Unlike many of the medical-marijuana companies producing and selling marijuana in states where it's legal, GW Pharmaceuticals isn't stuck in limbo...

Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings
at Investor's Business Daily - Fri Apr 18, 11:12AM CDT
Can biotech stocks bounce back? As recently as last month, the Medical-Biomed/Biotech group was ranked No. 1 out of IBD's 197 industries. But it's been dead last over the last four weeks, plunging 22.1%. That partly reflects growth stocks overall...

AbbVie Candidate in Pivotal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:32AM CDT
AbbVie's experimental cancer drug veliparib has been moved into a pivotal study.

Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...

Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 2.10% Gain
Comtex SmarTrend(R) - Wed Apr 16, 4:04PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.07 to a high of $294.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $292.80 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biogen Idec Rises 2.10% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 16, 4:04PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.07 to a high of $294.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $292.80 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.

3 Biotech Opportunities Following This Selloff
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 8:30AM CDT
Since the end of February, the iShares NASDAQ Biotechnology Index  has been hammered by about 19%. The most speculative companies have been the hardest hit, but several gems (with marketed products driving growth) have also taken a beating. ...

'Fast Money' Recap: Impressed by Yahoo!
at The Street - Wed Apr 16, 4:00AM CDT
The trading panel discussed Yahoo!'s earnings and Alibaba's IPO.

RBCC Bioprinting Partner Expands Brand Awareness Campaign
Business Wire - Wed Apr 16, 3:28AM CDT
Rainbow Coral Corp.'s (OTCBB: RBCC) 3D bioprinting partner, Nano3D Biosciences (n3D), has presented their groundbreaking technology at two high-profile events in recent weeks as part of a campaign to build brand awareness around the revolutionary BiO Assay system.

Health Care Stocks: Check Out This Low-Cost Market Beater
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 15, 4:15PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care stocks to your portfolio but don't have the time or expertise to hand-pick a few, the iShares US Healthcare ETF ...

Biotech Bubble Bust: 2 Ways to Win
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 1:08PM CDT
Are biotech stocks in a bubble? Is that bubble collapsing? These are the two questions at the forefront of investors' minds. Given the tremendous run of biotech stocks, the iShares NASDAQ Biotechnology Index  is up 80% over the last 2 years, it's...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading

Top 5 Most Recently Viewed Articles

Eaton Corp's Options Trading Insights and Market Analysis

Updated Category News Views 116

Understanding Eaton Corp's Options Trading Trends Recently, financial analysts have noticed a significant bearish trend when it comes to options trading for Eaton Corp (NYSE: ETN). Investigating the history of options trades has revealed insights into the market sentiment surrounding this industrial giant. A thorough analysis showed that a mere 11% of traders exhibited...

Continue Reading
Celebrating Community Resilience After Pacific Palisades Fires

Updated Category News Views 207

Community Resilience Shines in Pacific Palisades The recent reopening of the Casa Gateway affordable housing complex in Pacific Palisades brings a heartwarming sense of relief to many residents who faced the devastating impact of fires. Amidst the recovery efforts, stories of gratitude and hope shine through, demonstrating the importance of community support and...

Continue Reading
Stellantis Makes Bold Move with $41 Million Investment for Efficiency

Updated Category News Views 225

Stellantis Invests $41 Million for Enhanced Parts Delivery Stellantis (NASDAQ: STLA), the parent organization of popular automotive brands such as Jeep and Dodge, is taking significant steps towards improving its logistics capabilities with a substantial $41 million investment. This financial commitment is part of a broader strategy to modernize its parts distribution...

Continue Reading
Navigating the Shifts in Money Market Dynamics and Bank Reserves

Updated Category News Views 137

Understanding Current Dynamics in Money Markets The landscape of liquidity in the money markets is currently characterized by ample conditions. However, experts anticipate a reduction in bank reserves in the months ahead, leading to a potential tightening of conditions. With ongoing activity in market repurchase agreements (repo) and a robust issuance of treasury bills,...

Continue Reading
Harnessing AI and Human Intelligence for Personal Growth

Updated Category News Views 329

AI Happiness Accelerator Empowers Personal Growth Imagine if you could optimize your thoughts and emotions just like improving a website’s performance. The AI Happiness Accelerator (AHA) aims to do exactly that by leveraging cutting-edge Generative AI tools. Co-founder and Chief Information Officer Amy Chang emphasizes that success in all areas—personal, relational,...

Continue Reading